Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 947 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07135102RecruitingPhase 1
Radioactive drug for advanced prostate cancer
This study tests an experimental radioactive drug ([225Ac]Ac-PSMA-XT) that targets prostate cancer cells. It is for men whose prostate cancer has spread and stopped responding to standard hormone therapy and chemotherapy.
Jinan, ShandongAges 18 years+ - NCT07231705Recruiting
Plant-based formula for growth and tolerance in toddlers
This study tests how well toddlers (12-17 months old) tolerate and grow on a plant-based formula. It compares this new formula to standard ones for children who get most of their calories from formula.
Columbus, OhioAges 1 year–1.4 years - NCT07204574RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer after first treatment
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
TaoyuanAges 18 years+ - NCT07207408RecruitingPhase 2
Plague vaccine study for healthy adults
This study tests an experimental vaccine to protect against plague. It's for healthy adults 18 to 55 who haven't had plague or the vaccine before. The goal is to see if the vaccine is safe and creates a strong immune response.
Miami, FloridaAges 18–55 - NCT07060989RecruitingPhase 1/Phase 2
Study of NTS071 for advanced solid tumors with TP53 Y220C mutation
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
San Antonio, TexasAges 18 years+ - NCT06349837RecruitingPhase 1
Combination radiation and immunotherapy for large tumors
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
Chengdu, SichuanAges 18 years+ - NCT05541822RecruitingPhase 2
Study drug for lung cancer with specific c-MET changes
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Lake City, FloridaAges 18 years+ - NCT07259889RecruitingPhase 1
CEL001 injection safety study for advanced solid tumors
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
BeijingAges 18 years+ - NCT06132828RecruitingPhase 1
Testing DR30206 for advanced or metastatic solid tumors
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07262164RecruitingPhase 1
Testing VG2062 for advanced solid tumors
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
HebeiAges 18–75 - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9 - NCT06888830RecruitingPhase 1/Phase 2
Study of JS212 for advanced solid tumors
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT06724588Enrolling by invitation
Bacteria and drug resistance in people with repeat UTIs
This study looks at bacteria in urine samples from people who get frequent urinary tract infections and have a certain type of catheter. It aims to learn why some bacteria are hard to treat and may help improve care for patients like you.
LeuvenAges 18 years+ - NCT07042100RecruitingPhase 1
Safety study of SBO-154 for advanced solid tumors
This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.
Scottsdale, ArizonaAges 18 years+ - NCT05650866Recruiting
Testing an implanted device to help erections after prostate surgery
This trial checks whether a new implanted device is safe and tolerable to help improve erections after nerve-sparing prostate surgery. It may help men who want to reduce erectile side effects from prostatectomy, but it also excludes several groups who have erection-related problems or nerve issues.
Fitzroy, VictoriaAges 30–70 - NCT06828848RecruitingPhase 2
Study of Vaborem in children with Gram negative infections
This trial tests how Vaborem is absorbed and tolerated in children with serious bacterial infections, including complicated urinary tract infections. It aims to find the right dose for children.
OstravaAges birth–17 years - NCT06814717RecruitingPhase 2
Study of cP12 for adults with small burns
This trial tests a new drug called cP12 given through a vein to see if it is safe and how the body handles it. It is for adults who have a thermal burn covering 10% or less of their body within the first 2 to 24 hours after the burn happened.
Washington D.C., District of ColumbiaAges 18–65 - NCT07144462RecruitingEarly Phase 1
Testing a new drug for people with certain autoimmune diseases that have come back or not responded to treatment
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06672536RecruitingPhase 1/Phase 2
Study of SCT520FF for wet age-related macular degeneration
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
TianjingAges 45–80 - NCT07553429RecruitingPhase 1/Phase 2
Testing a new eye injection for diabetic swelling
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
Phoenix, ArizonaAges 18 years+ - NCT07430397RecruitingPhase 1
Safety study of CITY-FXI in healthy adults and those with clotting risks
This trial tests a new medicine, CITY-FXI, to see if it is safe and how it works in the body. It is for healthy adults and also for adults with specific genetic conditions (Factor V Leiden or Prothrombin G20210A mutation) that increase the risk of blood clots.
LondonAges 18–60 - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Los Angeles, CaliforniaAges 2–17 - NCT07368803RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for bile duct cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
Hangzhou, ZhejiangAges 18–75
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 947 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.